Author: [email protected]

Release – Conduent Teams with New Jersey to Roll Out Chip-Enabled SNAP Cards to Prevent EBT Theft

Posted on by [email protected]

October 20, 2026

Conduent Incorporated (Nasdaq: CNDT), a global technology-driven business solutions and services company, today announced its collaboration with the New Jersey Department of Human Services to provide people in need across the state with chip-enabled EBT cards designed to prevent benefit theft and protect their funds. The new cards, which are available to clients of the Supplemental Nutrition Assistance Program (SNAP) and the Work First New Jersey (WFNJ) cash assistance program, also allow for tap-to-pay functionality – making it the first Conduent-supported state to include this capability.

“We are excited to make these more secure cards available to all residents who participate in SNAP or the WFNJ program. The chip-enabled cards provide an added layer of security and are an important tool in our ongoing efforts to safeguard benefits and protect residents who rely on this assistance from this type of widespread benefit fraud,” said New Jersey Human Services Commissioner Stephen Cha.

EBT cards for SNAP and other benefits have traditionally relied on magnetic stripes that are vulnerable to skimming, where criminals install devices on point-of-sale terminals or ATMs to steal card information. With chips, New Jersey cardholders can now insert their cards into the terminals rather than swiping them, adding a critical layer of protection.

Beneficiaries in New Jersey can also use their EBT cards to access benefits using tap-to-pay functionality. This means cardholders can simply tap their cards at enabled terminals, reducing the risk of benefit theft while improving speed and ease of use.

Cardholders should continue to lock their card when not in use. New Jersey EBT cards can be locked and unlocked at NJFamiliesFirst.gov or by using the ConnectEBT app, which is available in Apple App Store or Google Play Store. In addition to engaging card lock features, cardholders should always maintain the privacy of their four-digit personal identification number (PIN) and identifying card information.

“As thieves increasingly have targeted taxpayer-funded government benefits in recent years, chip-enabled payment technology has emerged as a key tool to reduce EBT theft, improve account security and ensure critical funds go to rightful recipients,” said Anna Sever, President, Government Solutions at Conduent. “Conduent is proud to help states deploy this technology that also offers more flexible, fast and convenient payment options, such as tap-to-pay.”

Aside from New Jersey, Conduent continues to work with several other states that have transitioned, or are in the process of transitioning, to chip-enabled cards. Earlier this year, the company announced a collaboration with Alabama to become the second state to roll out chipped EBT cards to all its beneficiaries statewide.

The chip-enabled technology is among Conduent’s VeriSight Anti-Fraud Solutions , a suite of innovative offerings that help agencies address fraud and theft risks in public benefit programs. The suite also includes the lock and unlock capabilities with ConnectEBT, plus adaptive theft detection tools for EBT customer service centers that can identify and block suspicious activity, such as unusual phone numbers or high call volumes.

Conduent is a national leader in government payment disbursements, having disbursed approximately $80 billion in government benefit payments in 2025. Conduent also supports U.S. government agencies with end-to-end solutions for healthcare claims processing, eligibility and enrollment, and child support administration.

About Conduent

Conduent is a global technology-enabled operating partner that helps businesses and governments simplify complexity, modernize mission-critical operations and deliver measurable outcomes through AI, automation, data and human expertise. Learn more at www.conduent.com .

Note: To receive RSS news feeds, visit www.news.conduent.com . For open commentary, industry perspectives and views, visit https://x.com/Conduent , http://www.linkedin.com/company/Conduent or http://www.facebook.com/Conduent .

Trademarks

Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

Media Contact:
Neil Franz, Conduent, [email protected] , +1-240-687-0127

Investor Relations Contact:
Nick Goel, Conduent, [email protected]

Release – NanoViricides’ Revolutionary Broad-spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials

Posted on by [email protected]

Tuesday, 20 October 2026 08:45 AM

SHELTON, CT / ACCESS Newswire / October 20, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announces that its broad-spectrum antiviral drug NV-387 has successfully demonstrated strong safety, tolerability, and toxicological parameters in an animal model study involving juvenile mouse pups.

This study is expected to pave the way for pediatric use of NV-387 in clinical trials in children possibly as young as 1 year old.

Pediatric drugs for Ebola, Mpox, and Measles, as well as RSV – to name a few of the Company’s current or contemplated clinical trial programs – are unmet medical needs.

NV-387 is an extremely broad-spectrum antiviral drug that has demonstrated strong effectiveness in relevant animal models of multiple human viral infections. These include RSV, COVID, Influenza, Mpox, Smallpox, and Measles.

The Impact of the Juvenile Animal Model Study of NV-387 Treatment

NV-387 Oral Gummies formulation is currently in a Phase II clinical trial for the treatment of Ebola in the Democratic Republic of Congo (DRC). The novel Ebola Bundibugyo virus is known to disproportionately affect children i. NanoViricides anticipates being able to add a pediatric cohort in a Phase III registrational clinical trial, assuming the drug is found to be effective in the current Phase II clinical trial. If successful, NV-387 will likely be the first and only treatment for Ebola virus infection in children. There is no approved treatment nor an approved vaccine for the Ebola Bundibugyo virus.

NV-387 is also currently in another Phase II clinical trial for the treatment of Mpox in the Democratic Republic of Congo (DRC). Mpox Clade I, which is the currently most prevalent version of this virus, is known to disproportionately affect children. There is no approved treatment for Mpox. If Phase II is successful, we intend to add a pediatric cohort in the following Phase III registrational clinical trial.

NV-387 as a Treatment for Measles was granted an Orphan Drug Designation as well as a Rare Pediatric Disease Drug Designation by the US FDA. Measles primarily affects children. There is no approved treatment for Measles. The Company intends to perform a Phase II and, if successful, a Phase III clinical trial for NV-387 as a Treatment for Measles, towards a US FDA Marketing Authorization Application. If the program is successful and MAA is granted, then the Company will be eligible for a Priority Review Voucher (PRV). A PRV can fetch around $200 million if sold to another Pharma company ii, enabling substantial revenues even prior to achieving significant commercial sales.

The Juvenile Animal Model Study of NV-387 Oral Gummies Treatment and Results

Under the conditions of this study, the No Observed Adverse Effect Level (NOAEL) was determined to be 1,230 mg/kg per dose administered three times daily, or 3,690 mg/kg/day, or a total cumulative drug exposure of 44,280 mg/kg over the 12 day dosing period. This was actually the highest dose level tested. Therefore, a Maximum Tolerable Dose (MTD) could not be estimated iii.

These numbers are indicative of extremely strong safety and will enable a wide range for dosing of NV-387 in pediatric clinical trials for the treatment of various viral diseases.

A 12 Day Repeated-Dose Safety/Tolerability, Toxicity and Toxicokinetic Study with a 14-Day Recovery Period in Juvenile Balb/c Mouse Pups, was conducted to evaluate the safety/tolerability, toxicity and toxicokinetic profile of NV-387 Oral Gummies, containing the active pharmaceutical ingredient (API) NV-387. The Juvenile Balb/c mouse pups received NV-387 Oral Gummies formulation doses three times daily for up to 12 consecutive days, followed by recovery period to assess persistence, reversibility, or delayed occurrence of any treatment-related effects.

NV-387 Oral Gummies were well tolerated at all dose levels, including the highest dose of 1,230 mg/kg per dose amounting to drug exposure of 3690 mg/kg/day, or a total cumulative drug exposure of 44,280 mg/kg over the 12 day dosing period. There was no mortality, systemic toxicity, treatment-related clinical observations, adverse effects on body weight gain, alterations in cardiovascular parameters, changes in clinical pathology, or treatment-related gross or microscopic pathological findings observed in either sex.

Most Recent Annual Report

The “Company” has previously reported that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2026 with the Securities and Exchange Commission (SEC) on Monday, September 28, 2026. The report can be accessed at the SEC website (https://www.sec.gov/ix?doc=/Archives/edgar/data/0001379006/000110465926111390/nnvc-20260630x10k.htm). The Company’s Financial Statements included in its Annual Report on Form 10-K for the fiscal year ended June 30, 2026, contained an audit report from its Independent Registered Public Accounting Firm with an explanatory paragraph emphasizing that the audit opinion expressed substantial doubt about its ability to continue as a going concern. Release of this information is required by Section 610(b) of the NYSE American Company Guide and does not reflect any change or amendment to any of the Company’s filings for the fiscal year ended June 30, 2026.

Management’s Plan of Financing Activities, in Particular, Financing Clinical Trials

Management believes that the Company is working on diseases of global importance with a potential for a high positive impact. In particular, the Phase II Clinical Trial of NV-387 Oral Gummies for the Treatment of Ebola Virus Disease in DRC, is addressing a global high priority concern.

The USA has been, laudably, and proudly, the largest provider of humanitarian and relief assistance in this Ebola outbreak, with almost $1.4 Billion in contributions. The USA has already provided $887 Million, and has pledged another $500 Million, of which $267 million has been released, according to the US Department of State iv. This includes support for various public health measures, on site personnel, as well as funding for clinical trials of drugs and vaccines that were already under the auspices of US Government agencies. All of these supported drugs require infusions, a procedure that is not scalable for response in such a rapidly growing outbreak that the current Ebola Bundibugyo virus outbreak has turned out to be.

We believe that NV-387 being the only oral treatment in clinical trial for Ebola, there is a strong potential for non-dilutive funding for this regulatory development of NV-387 towards licensure. Management is continuing to work on obtaining non-dilutive funding for NV-387 as a unique and novel broad-spectrum antiviral, that we believe is revolutionary in the field of treatment of viral diseases, and now, in particular, for Ebola.

Additionally, we plan on continuing our efforts at financing the Company, when opportune, through different equity-based funding routes. In particular, the Company has an “At-the-Market” facility with an investment brokerage house, for issuing and selling common shares directly to investors.

Additional details can be found in the annual report filing.

Forward Looking Statements

Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, earnings and Adjusted EBITDA, the ability to realize firm backlog and projected backlog, cost cutting measures, potential future results and acquisitions, are examples of such forward-looking statements. The forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of projects due to variability in size, scope and duration, the inherent discrepancy in actual results from estimates, projections and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
[email protected]

Public Relations Contact:
[email protected]

Source: NanoViricides, Inc.

Euroseas (ESEA) – Strong Charter Rates and Attractive Vessel Sale

Posted on by [email protected]


Tuesday, October 20, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New charter at an attractive rate. Euroseas announced a new time charter for its 2001-built, 2,556 twenty-foot equivalent unit (TEU) feeder containership, M/V EM Corfu, at a gross daily rate of $62,500 for a minimum period of 12 to a maximum period of 14 months. The charter, expected to commence in mid-December following a scheduled dry-dock, represents a significant increase from the previous rate of $28,000 per day. The new charter is expected to generate approximately $17.8 million in EBITDA over the minimum 12-month period. The agreement increases charter coverage to approximately 100% for 2026, 91% for 2027, and 49% for 2028.

Monetizing an older vessel. Euroseas also agreed to sell the M/V Evridiki G, a 2001-built sister vessel of the EM Corfu, for approximately $26 million. The transaction is expected to generate a gain of $22.5 million, or $3.19 per share. We view the sale favorably given the vessel’s age and the opportunity to realize an attractive price while reducing the fleet’s exposure to older tonnage.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Salesforce to Acquire Braze for $5.7 Billion as AI-Powered Marketing Competition Intensifies

Posted on by [email protected]

The $47.50-per-share deal represents a 58% premium as Salesforce expands its customer engagement capabilities and strengthens its position in AI-driven enterprise software.

Salesforce (NYSE: CRM) has announced an agreement to acquire customer engagement platform Braze (NASDAQ: BRZE) for approximately $5.66 billion in enterprise value, marking another major investment in artificial intelligence and enterprise software. The all-cash transaction, announced October 20, offers Braze shareholders $47.50 per share, representing a roughly 58% premium to the company’s previous closing price of $30.04.

The acquisition is designed to strengthen Salesforce’s marketing technology capabilities by combining its customer relationship management platform with Braze’s real-time customer engagement tools. The deal reflects growing demand for AI-powered software that helps businesses personalize customer interactions, improve marketing efficiency, and increase customer retention.

Braze specializes in helping companies communicate with customers across multiple digital channels, including email, mobile applications, websites, text messaging, and WhatsApp. Its technology analyzes customer behavior and allows businesses to deliver personalized messages based on individual preferences, purchasing activity, and engagement patterns.

The company serves approximately 2,770 customers, including Canva, Instacart, Urban Outfitters, Venmo, and Equinox. Its AI-powered platform, BrazeAI, helps businesses determine the most effective content, communication channels, and timing for customer interactions.

For Salesforce, the acquisition represents an opportunity to expand its Marketing Cloud platform while integrating Braze’s capabilities with its broader artificial intelligence strategy. Salesforce has increasingly focused on developing autonomous AI agents through Agentforce, enabling businesses to automate customer service, sales, and marketing activities.

Combining these technologies could allow businesses to move beyond traditional marketing automation toward more intelligent systems capable of responding to customer behavior in real time. For example, an AI-powered platform could identify when a customer abandons an online purchase and automatically deliver a personalized offer through the most effective communication channel.

The transaction also highlights intensifying competition across the enterprise software industry as major technology providers race to incorporate artificial intelligence into their products. Companies are investing heavily in automation, predictive analytics, and customer data platforms to help businesses improve productivity and generate measurable returns from AI adoption.

Investor reaction reflected the significant premium attached to the acquisition. Braze shares surged approximately 51% in early trading following the announcement, while Salesforce shares declined around 2% as investors evaluated the purchase price and potential integration costs.

The acquisition values Braze at more than six times projected annual revenue, illustrating the substantial valuations being placed on software companies offering differentiated AI capabilities and recurring subscription revenue.

For investors, the transaction reinforces the strategic importance of customer data and personalized engagement as businesses increasingly adopt artificial intelligence. It also raises questions about whether larger software companies can successfully integrate acquired technologies while maintaining profitability and delivering meaningful returns on investment.

The deal is expected to close during Salesforce’s fiscal year 2028, subject to shareholder approval, regulatory clearance, and customary closing conditions. Salesforce indicated that the acquisition is not expected to change its fiscal 2027 financial guidance.

The $5.7 billion transaction underscores a broader shift in enterprise technology, where artificial intelligence is transforming how companies interact with customers. As competition intensifies, businesses offering advanced automation, real-time analytics, and AI-driven personalization could become increasingly attractive acquisition targets for larger technology companies seeking to expand their capabilities.

Lycia Therapeutics Targets $250 Million IPO as Biotech Market Rebounds

Posted on by [email protected]

Lycia Therapeutics is preparing to raise approximately $250 million through an initial public offering, becoming the latest biotechnology company seeking to capitalize on renewed investor interest in emerging drug developers. The South San Francisco-based company announced plans Tuesday to offer 14.7 million shares priced between $16 and $18 each, potentially valuing the business at approximately $950 million on a fully diluted basis.

The company intends to list on the Nasdaq under the ticker symbol LYCA, adding another early-stage biotechnology developer to a growing pipeline of healthcare IPOs. The offering comes as investors increasingly look beyond established pharmaceutical companies toward emerging businesses developing innovative treatments for diseases with significant unmet medical needs.

Lycia is developing a new class of medicines designed to eliminate disease-causing proteins from the body. Its proprietary LYTAC technology, short for Lysosomal Targeting Chimera, works by directing specific proteins toward the body’s natural cellular disposal system. Unlike traditional drugs that primarily block the activity of harmful proteins, Lycia’s approach aims to remove them altogether.

The technology is based on research associated with Nobel Prize-winning chemist Carolyn Bertozzi, who helped establish the company in 2019. Lycia is initially targeting autoimmune, inflammatory, and allergic diseases, areas where conventional treatments often require ongoing symptom management.

Its lead experimental treatment, LCA-0061, is being developed for food allergies and other allergic conditions. The therapy targets immunoglobulin E, or IgE, an antibody responsible for triggering many allergic reactions. Early Phase 1 results showed a mean maximum IgE reduction of 96% from baseline among treated participants in an initial small cohort, although larger studies will be needed to determine its safety and effectiveness in patients.

Lycia is also developing LCA-0321, an experimental treatment for Graves’ disease, an autoimmune condition affecting the thyroid. The candidate is designed to selectively eliminate disease-causing antibodies rather than broadly suppress the immune system.

Lycia’s focus on targeted therapies for autoimmune and inflammatory conditions also reflects broader innovation across the biotechnology sector. Eledon Pharmaceuticals (NASDAQ: ELDN) is developing tegoprubart, an investigational treatment designed to regulate immune system activity by targeting the CD40 ligand pathway, with applications in organ transplantation. Meanwhile, Gyre Therapeutics (NASDAQ: GYRE) is focused on developing treatments for inflammatory and fibrotic diseases, including liver-related conditions. Although these companies employ different scientific approaches, their development programs highlight growing interest in therapies that address specific biological mechanisms underlying complex diseases.

Proceeds from the IPO are expected to support clinical development of these programs, additional research activities, and general corporate operations. The company has already raised approximately $267 million from private investors, including several prominent life sciences investment firms.

The planned offering follows a series of biotechnology IPOs that suggest improving conditions for companies seeking public-market financing. City Therapeutics and Iambic Therapeutics recently completed offerings that raised approximately $350 million combined, highlighting investor interest in RNA-based medicines and artificial intelligence-driven drug discovery.

While these companies are pursuing different technologies, their emergence reflects a broader shift toward specialized drug development platforms that could generate multiple treatments across different diseases.

For investors, Lycia’s proposed IPO offers exposure to an emerging area of biotechnology known as targeted protein degradation. The technology could eventually expand treatment possibilities for diseases where existing therapies have limited effectiveness, although its clinical and commercial potential remains unproven.

The offering also carries substantial risks. Lycia remains an early-stage clinical developer without an approved commercial product, and its future valuation will depend heavily on clinical trial results, regulatory progress, and its ability to finance continued research.

As more biotechnology companies test public-market demand, Lycia’s offering could provide another indication of whether investor appetite for early-stage drug developers is strengthening heading into the final months of 2026.

Two Biotech IPOs Raise $350 Million as Investor Appetite for New Drug Developers Rebounds

Posted on by [email protected]

City Therapeutics and Iambic Therapeutics make strong Nasdaq debuts, highlighting renewed interest in RNA-based medicines and AI-powered drug discovery.

The biotechnology IPO market showed fresh signs of momentum last week as City Therapeutics (NASDAQ: CTY) and Iambic Therapeutics (NASDAQ: IAM) raised a combined $350 million in public offerings. Both companies attracted strong investor interest and delivered positive first-day trading performances, suggesting that demand for emerging drug developers may be improving despite broader market volatility.

City Therapeutics, a Cambridge, Massachusetts-based biotechnology company developing RNA interference (RNAi) medicines, raised approximately $200 million through an upsized initial public offering. The company sold 11.1 million shares at $18 each, exceeding its original fundraising target, and began trading on the Nasdaq on October 16.

Shares climbed approximately 24% during their first trading session, closing at $22.40 and giving the company a strong public-market debut.

Founded in 2023, City Therapeutics focuses on RNAi technology, which works by silencing specific genes responsible for producing disease-related proteins. Its lead candidate, CITY-FXI, is undergoing Phase 1 clinical testing for thromboembolic diseases, conditions involving potentially dangerous blood clots.

The company’s broader pipeline includes CITY-RBP4, targeting Stargardt disease and other retinal disorders, and CITY-TFR2, being developed for anemia associated with chronic diseases. The IPO proceeds will help advance these programs through clinical development.

Meanwhile, San Diego-based Iambic Therapeutics raised $150 million through the sale of approximately 9.4 million shares priced at $16 each. The company began trading on October 15 under the ticker IAM, with shares gaining approximately 13% during their first session.

Iambic represents a different segment of biotechnology innovation, combining artificial intelligence with automated laboratory experimentation to accelerate drug discovery.

Its proprietary technology uses AI models to analyze molecular structures, predict drug behavior, and identify promising therapeutic candidates. The company believes this approach can reduce the time and resources traditionally required to discover and develop new medicines.

Iambic’s lead clinical candidate, IAM1363, is an experimental cancer treatment discovered using its AI-powered platform. The company also maintains a pipeline of additional oncology programs and partnerships with established pharmaceutical companies.

Investor interest in Iambic was supported by prominent institutional backers, including ARK Investment Management and Duquesne Family Office, which indicated interest in purchasing up to $60 million of shares in the offering. Nvidia has also established an investment and technology relationship with the company.

The successful debuts arrive during a period when biotechnology companies have faced challenging financing conditions, with higher capital costs and investor caution limiting access to public markets.

However, these offerings suggest investors remain willing to support companies with differentiated technologies, promising drug pipelines, and credible development strategies.

The contrasting approaches of City Therapeutics and Iambic also highlight two important investment themes. RNA-based therapies are expanding the range of diseases that can potentially be treated through targeted genetic mechanisms, while artificial intelligence is creating new opportunities to improve drug discovery efficiency.

Still, both companies remain clinical-stage developers, meaning their long-term success depends on achieving favorable clinical trial results, securing regulatory approvals, and eventually commercializing their treatments.

For investors, the combined $350 million raised and positive trading debuts provide encouraging evidence that the biotechnology IPO market may be regaining momentum. Whether that momentum continues will depend on broader market conditions, future clinical milestones, and the performance of newly listed companies.

The strong reception for City Therapeutics and Iambic suggests that innovative biotechnology remains an attractive investment opportunity, particularly where emerging technologies offer the potential to address significant unmet medical needs.

The contrasting approaches of City Therapeutics and Iambic highlight growing investor interest in innovative drug development platforms. That interest extends to smaller publicly traded biotechnology companies advancing novel treatments, including Ocugen (NASDAQ: OCGN), which is developing gene therapies for inherited retinal diseases, and MAIA Biotechnology (NYSE American: MAIA), which is advancing its investigational telomere-targeting cancer treatment, ateganosine. While these companies pursue different scientific approaches, they reflect the broader investment focus on targeted therapies addressing unmet medical needs. Meanwhile, Merck KGaA’s $1.3 billion acquisition of Silence Therapeutics further underscores the strategic value pharmaceutical companies are placing on emerging RNA-based medicines.

Release – The GEO Group Completes Redemption of All Senior Secured Notes Due 2029

Posted on by [email protected]

October 19, 2026

PDF Version

BOCA RATON, Fla.–(BUSINESS WIRE)–Oct. 19, 2026– The GEO Group, Inc. (NYSE: GEO) (“GEO” or the “Company”) announced today that it completed the redemption of all of the $650,000,000 in outstanding aggregate principal amount of its 8.625%Senior Secured Notes due 2029 (CUSIP Nos. 36162JAG1 and U32352AF0) (the “2029 Senior Secured Notes”) on October 15, 2026 (the “Redemption Date”).

The redemption price for the 2029 Senior Secured Notes was equal to $1,043.13 per $1,000.00 original principal amount, or approximately $678 million, plus any accrued and unpaid interest up to, but excluding, the Redemption Date. The Indenture governing the 2029 Senior Secured Notes has been discharged. Payment of the redemption price for the 2029 Senior Secured Notes was made through the Depository Trust Company.

On October 6, 2026, GEO previously announced the closing of an amendment to the Company’s Amended Credit Agreement to extend the maturity of its $550 million Revolving Credit Facility to July 14, 2031 and to increase the Company’s restricted payments capacity. As of October 19, 2026, GEO had no outstanding borrowings under its Revolving Credit Facility.

Following this amendment and the discharge of the Indenture governing the 2029 Senior Secured Notes, GEO is permitted to make unlimited restricted payments, including share repurchases, under the Amended Credit Agreement, to the extent the Company’s total leverage ratio (as defined therein) calculated on a pro forma basis after giving effect to such restricted payment would be equal to or less than 2.25 to 1.00 and no default exists thereunder. Additionally, under the Indenture governing the Company’s $625 million 10.25% Senior Unsecured Notes due 2031, GEO is permitted to make unlimited restricted payments, including share repurchases, to the extent the Company’s consolidated total leverage ratio (as defined therein) calculated on a pro forma basis after giving effect to such restricted payment would be equal to or less than 2.00 to 1.00 and no default exists thereunder. On October 5, 2026, GEO previously announced that its Board of Directors approved a $750 million increase to the Company’s share repurchase authorization program, which is effective through December 31, 2029, from $500 million to $1.25 billion.

Following the redemption of the 2029 Senior Secured Notes, GEO’s outstanding gross debt totaled $625 million as of October 19, 2026, excluding mortgage debt on the Company’s Headquarters building with current principal balance of approximately $36 million.

About The GEO Group

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 97 facilities totaling approximately 76,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 20,000 employees.

Use of forward-looking statements

This news release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the cautionary statements and risk factors contained in GEO’s filings with the U.S. Securities and Exchange Commission including its Form 10-K, 10-Q and 8-K reports. All forward-looking statements speak only as of the date of this news release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements. Readers are strongly encouraged to read the full cautionary statements and risk factors contained in GEO’s filings with the U.S. Securities and Exchange Commission, including those referenced above. GEO disclaims any obligation to update or revise any forward-looking statements, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261016246329/en/

Pablo E. Paez (866) 301 4436
Executive Vice President, Corporate Relations

Source: The GEO Group, Inc.

Release – NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

Posted on by [email protected]

CAMBRIDGE, Mass., Oct. 19, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense” or the “Company”), a late-stage clinical biotechnology company developing treatments for neurodegenerative diseases, today announced that it has filed a patent application with the U.S. Patent and Trademark Office covering methods of treating traumatic brain injury (TBI) and related central nervous system injuries with the combination of ciprofloxacin and celecoxib, the active ingredients of PrimeC.

The application covers the treatment of a broad range of brain injuries, from concussion and mild TBI to moderate and severe TBI, including blast-related injury, as well as their long-term consequences, such as chronic traumatic encephalopathy (CTE). If granted, the patent is expected to provide protection through 2047, subject to any extensions.

Traumatic brain injury (TBI) represents a major global healthcare challenge, affecting millions of people each year. TBI can result from falls, motor vehicle accidents, sports-related injuries and military-related trauma, including blast exposure. Its consequences can extend well beyond the initial event, potentially causing persistent cognitive, physical and behavioral impairment, with substantial burdens on patients, caregivers and healthcare systems. Despite this significant unmet medical need, there are currently no approved disease-modifying therapies specifically targeting the secondary neurological injury associated with TBI.

Following the initial trauma, TBI can trigger complex biological processes, including neuroinflammation, oxidative stress and progressive neuronal damage. Certain mechanisms overlap with pathways implicated in neurodegenerative disorders.

The patent filing also supports NeuroSense’s longer-term strategy of pursuing additional applications for PrimeC beyond its existing development programs. The Company views TBI as an opportunity to broaden PrimeC’s commercial potential and build additional long-term value around its lead asset. While ALS remains NeuroSense’s primary development priority, the Company is evaluating future TBI-focused research and development initiatives, through strategic collaborations, research grants and other non-dilutive funding opportunities.

“While ALS remains our primary focus, we believe PrimeC may have potential across a broader range of neurological conditions that share common underlying disease mechanisms,” said Alon Ben-Noon, Chief Executive Officer of NeuroSense. “TBI is a particularly compelling area given the large affected population, the long-term consequences of brain injury and the lack of approved disease-modifying treatments. This filing strengthens our intellectual property position and creates a foundation for future research, partnerships and non-dilutive funding opportunities, while maintaining our focus on advancing our core ALS program. We look forward to sharing further updates as our clinical and strategic initiatives advance.”

About NeuroSense

NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The Company’s lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.

NeuroSense has recently completed analysis of long-term follow-up data from its Phase 2b PARADIGM study in ALS, with results published in JAMA Neurology showing slower functional decline in participants who received PrimeC from study start than in those who initially received placebo. The Company also reported changes across multiple biomarkers associated with ALS, including microRNAs, consistent with PrimeC’s multi-target mechanism of action.

NeuroSense has received clearance from the U.S. Food and Drug Administration (FDA) to initiate its pivotal Phase 3 clinical trial (PARAGON) in ALS, to be conducted primarily in the United States. The Company is working with FDA on an optimized design for the study.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

About PrimeC

PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to target several key mechanisms that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation, with the potential to inhibit disease progression.

About ALS

Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes progressive paralysis and, typically, death within 3 years of symptoms onset. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the Company’s development program, including for ALS and TBI, the potential issuance, scope and duration of patent protection arising from the Company’s patent application, including expected protection through 2047, subject to any extensions, the potential of PrimeC to treat TBI and related central nervous system injuries, the potential expansion of PrimeC beyond ALS and its potential commercial benefits and long-term value. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. These risks include the risk that the patent application will not result in an issued patent or that any patent granted will not provide the Company with the anticipated scope or duration of protection or will be challenged, invalidated or unenforceable; the risk that PrimeC will not demonstrate safety or efficacy in TBI or related conditions; the potential for delay in the timing of the Phase 3 clinical trial (PARAGON) in ALS; the risk that the Company will not be able to obtain financing on acceptable terms, or at all; the risk that the Company will not regain and maintain compliance with the Nasdaq listing requirements; the risk that non-dilutive grant funding for the PARAGON trial will not be awarded or will be delayed; uncertainty regarding outcomes and the timing of current and future clinical trials; the risk that PrimeC will not advance towards later-stage development; timing for reporting data, including from the study of PrimeC in Alzheimer’s disease; that the study will not be successful; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

SOURCE NeuroSense

For further information: For further information: Email: [email protected] | Tel: +972-(0)9-799-6183

Merck to Acquire Silence Therapeutics for $1.3 Billion in Major Gene-Silencing Biotech Deal

Posted on by [email protected]

The $20-per-share acquisition represents a 130% premium as Merck expands its rare disease pipeline and strengthens its position in RNA-based medicines.

German pharmaceutical and technology company Merck KGaA has agreed to acquire Silence Therapeutics (NASDAQ: SLN) in an approximately $1.3 billion all-cash transaction, highlighting growing interest in gene-silencing therapies and rare disease treatments. The deal, announced Monday, October 19, offers Silence shareholders $20 per American Depositary Share (ADS), representing a substantial 130% premium to the company’s closing price of $8.68 on Friday.

The acquisition values Silence Therapeutics at approximately $1.3 billion in equity and $1.1 billion in enterprise value. The purchase price also represents an 82% premium to the company’s 30-day volume-weighted average share price, underscoring the strategic value Merck places on its emerging drug pipeline.

At the center of the transaction is divesiran, an experimental RNA-based treatment targeting polycythemia vera, a rare form of blood cancer characterized by the excessive production of red blood cells. The condition can increase the risk of blood clots, strokes, and other serious cardiovascular complications, often requiring patients to undergo regular blood removal procedures to control their red blood cell levels.

Divesiran uses small interfering RNA (siRNA) technology to selectively silence a gene involved in regulating iron metabolism. By limiting iron availability for red blood cell production, the therapy aims to reduce the need for frequent blood removal treatments while improving disease management.

Recent Phase 2 clinical trial results have strengthened the drug’s potential. In the SANRECO study, divesiran achieved an 88% response rate compared with 19% for patients receiving placebo. Patients receiving the experimental therapy also required significantly fewer blood removal procedures, providing encouraging evidence ahead of planned Phase 3 development.

One potential advantage of divesiran is its dosing schedule. The treatment is designed to be administered through an injection once every three months, potentially offering patients a more convenient alternative to therapies requiring more frequent administration.

For Merck, the acquisition represents another step in its strategy to expand into specialized treatments addressing significant unmet medical needs. The company previously acquired SpringWorks Therapeutics in 2025, strengthening its presence in rare diseases and oncology. Adding Silence Therapeutics provides access to a promising late-stage drug candidate and a broader platform for developing RNA-based medicines.

The transaction also highlights the growing importance of gene-silencing technology within the biotechnology industry. Unlike traditional medicines that target proteins after they are produced, siRNA therapies work by reducing the production of specific disease-related proteins, potentially offering more targeted treatment approaches.

For biotechnology investors, the 130% acquisition premium demonstrates how promising clinical data can significantly increase the strategic value of smaller drug developers. Large pharmaceutical companies continue seeking innovative assets to replenish their pipelines, diversify revenue streams, and establish positions in emerging treatment categories.

However, divesiran remains investigational and must successfully complete additional clinical testing before potentially receiving regulatory approval. Its commercial prospects will depend on demonstrating sustained effectiveness, safety, and competitive advantages over existing treatments.

The transaction has received unanimous approval from Silence Therapeutics’ board and is expected to close during the first quarter of 2027, subject to shareholder, regulatory, and court approvals.

The acquisition reinforces a broader trend in biotechnology: pharmaceutical companies are increasingly willing to pay substantial premiums for innovative therapies supported by promising clinical results. As RNA-based medicine continues advancing, smaller biotechnology companies developing differentiated treatments could attract further acquisition interest from larger industry players.

Kodiak Copper Corp. (KDKCF) – Kodiak Extends Ketchan Mineralization, Strengthening Resource Potential

Posted on by [email protected]


Monday, October 19, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Ketchan deposit expands significantly. Kodiak Copper recently reported encouraging results from seven drill holes totaling 1,583 meters at its 100%-owned MPD copper-gold project in British Columbia. Step-out drilling extended the known mineralized envelope at Ketchan by at least 450 meters southeast of its existing 1.4-kilometer resource footprint, increasing the known extent of the mineralized system and supporting potential resource growth.

Near-surface copper-gold mineralization. Hole AG-26-034 intersected 122.5 meters grading 0.41% copper equivalent (CuEq), beginning just 5.5 meters below the surface. Hole AG-26-021 returned 202.5 meters grading 0.20% CuEq, while infill hole AG-26-015 intersected 207.3 meters grading 0.31% CuEq. The results demonstrate mineralization both beyond and within the existing resource boundaries.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

First Phosphate Corp. (PHOS) – Advancing Toward Feasibility

Posted on by [email protected]


Monday, October 19, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Significant progress toward development. First Phosphate continues to advance its North American LFP battery materials strategy, supported by its inclusion in a G7-backed critical minerals initiative, international financing interest, accelerated permitting coordination in Quebec, and expanded mineral resources. These developments strengthen the company’s strategic position as Bégin-Lamarche advances toward feasibility.

Strengthening project economics and financing prospects. With the updated mineral resource estimate, indicated mineral resources increased by 378%, providing greater geological confidence for feasibility-level mine planning. Canadian government contributions and potential export credit support from Swiss and Danish agencies could reduce future funding requirements. Management is targeting completion of the Bégin-Lamarche feasibility study in the first quarter of calendar 2027.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Conduent (CNDT) – Conduent Moves To Resolve Major Litigation Overhang

Posted on by [email protected]


Monday, October 19, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Reaches $80 million class action settlement. Conduent agreed to settle consolidated class action litigation related to its previously disclosed January 2025 cybersecurity incident. The incident involved unauthorized access to the company’s networks beginning in October 2024 and exposed personal information belonging to approximately 62 million individuals. The agreement remains subject to court approval.

Addresses significant litigation exposure. The settlement seeks to resolve litigation stemming from the cybersecurity incident, including claims involving Conduent and affected clients. Upon final approval, the agreement would release Conduent, its affected clients, and their affected customers from covered claims arising from the incident. We believe the agreement provides greater visibility into a significant legal uncertainty that has weighed on the company’s broader turnaround efforts.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Kratos Defense & Security (KTOS) – A Tuck-in and Other News

Posted on by [email protected]


Monday, October 19, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A Tuck-in. Last week, Kratos acquired Jetset Airmotive from its founders. Jetset’s MRO operations on PT6A turbine engines complement Kratos’ existing MRO operations conducted through its Oklahoma-based CTS subsidiary. Based on previous such transactions, we believe the acquisition was structured as 50% KTOS shares and 50% cash, which would imply roughly $50 million in total. With an estimated $40-$50 million in revenue and typical 13-14% EBITDA margins, Jetset was purchased for approximately 1x revenue and 9x EBITDA. The acquisition should add about $5+ million to annual EBITDA.

New Contracts. Kratos has been awarded more than $100 million over multiple contracts to develop prototype mission applications and cyber capabilities, providing space intelligence data in support of joint operations across the space and cyberspace domains. The contracts will leverage Kratos’ software products, analytics, and expertise in RF, signal processing, cybersecurity, and software development, establishing a proven technology base that can be adapted and integrated to meet emerging space and cyber mission requirements.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.